Author

Anup Malani

Anup Malani is the Lee and Brena Freeman Professor at the University of Chicago Law School and a Professor at the Pritzker School of Medicine. He is also a Research Associate at the National Bureau of Economic Research in Boston. He is an elected member of the American Academy of Arts and Sciences and has served on the boards of the Becker-Friedman Institute, the Neubauer Collegium and the University of Chicago Press. Malani was the founding Faculty Director of the Tata Centre for Development at the University of Chicago. He is also the co-founder and Faculty Director of the International Innovation Corps, a social service program that sends teams of US and foreign university graduates to work on innovative development projects with government officials in India and Brazil.

  • Antitrust

    Reverse Settlements, Part 4: What Is the Baseline?

    By Anup Malani In my final post on reverse settlements I want to offer three thoughts that are more directly related to the legal question of how to treat reverse settlements under antitrust law. First,…

    Reverse Settlements, Part 4: What Is the Baseline?

  • Antitrust

    Reverse Settlements, Part 3: Value of a Drug Patent

    By Anup Malani In this third post on reverse settlements, I examine whether traditional legal standards for judging whether a drug patent is valid captures the social value from a drug patent.  This is important…

    Reverse Settlements, Part 3: Value of a Drug Patent

  • Biotechnology

    Reverse settlements, Part 2: drug company profits

    By Anup Malani In my second post, I want  continue my discussion of reverse settlements.  Recall that the basic argument against reverse settlements is that they extend the duration of a pioneer drug company’s patent…

    Reverse settlements, Part 2: drug company profits

  • Biotechnology

    A different perspective on reverse settlements

    By Anup Malani  Before I begin my initial post, I want to thank Holly for inviting me to post on this blog. I want to take up reverse settlements in litigation over pharmaceutical patents. Circuits…

    A different perspective on reverse settlements